Do you have Hodgkin's Lymphoma or Cutaneous T-Cell Lymphoma? Has your lymphoma come back, or has it not gotten better after your last treatment? If so, you might be able to take part in a study that will modify your own immune cells to see if it may treat your lymphoma.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.

Have you been diagnosed with melanoma? If so, you may be eligible to take part in a research study looking at the safety of giving a combination of drugs called Ulixertinib and Palbociclib to patients with advanced melanoma.

Have you been diagnosed with Acute Lymphoblastic Leukemia? Has your leukemia come back or didn't get better after your last treatment? If so, you may be able to take part in a research study to learn more about the safety of modifying your own immune cells to treat your leukemia.

Do you have bladder, kidney, prostate, or another genitourinary cancer diagnosis? If so, you may be able to take part in a research study collecting specimens (e.g., blood, urine, saliva, tissue) during your already scheduled appointments. Collecting these specimens may help researchers develop new ways to detect cancer earlier or to more effectively treat cancer.

This study will collect information from colorectal surgeons throughout the United States with regard to their access to pelvic exenteration surgery for their patients with rectal cancer. We will assess their personal comfort with performing the procedure as well as their perceived access to colleagues who can provide the procedure. We will also assess educational and support needs amongst colorectal surgeons with regard to pelvic exenteration.

The purpose of this study is to develop and validate an Artificial intelligence (AI)-based tissue sample analysis tool that can predict response & progression rates to chemotherapy in intermediate-risk (IR) and high-risk (HR) Non-muscle invasive bladder cancer (NMIBC) patients. This study will use AI-based tissue sample analysis as a possible tool to help predict which patients are at high-risk for cancer recurrence and progression after surgery and chemotherapy treatment. Specimens will be obtained for each patient before treatment and at the 12, 24, & 36 month follow-up to be analyzed using the AI-based tool.

To compare disease-free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone.

The purpose of this study is to learn what women with HIV think about cervical cancer screening. We also want to talk about the idea of using HPV self-collection (where women collect their own sample) instead of going to the clinic for testing. This information will help us see if self- collection can help more women with HIV get screened for cervical cancer.

To provide AMTAGVI per United States Prescribing Information (USPI) to patients.